Cochlear Reaffirms FY27 Guidance Ahead of Investor Day
The hearing implant maker kept its FY27 profit forecast as it prepares for a Capital Markets Day and announces a senior leadership departure.
Updated on Nov. 12, 2026 in Corporate Finance

Cochlear reaffirmed its FY27 underlying net profit guidance of $330 million to $350 million and said trading from July to October remained in line with its expectations. The company also said its assumptions from the August full-year results remain unchanged.
Why it matters
The reaffirmed guidance gives investors a fresh read on the company's outlook before its Capital Markets Day. The announced departure of its North American president adds a leadership change to watch in the company's key markets.
Cochlear reaffirmed FY27 underlying net profit guidance of $330 million to $350 million, with developed-market implant volumes growing at a mid-single-digit rate between July and October. The update does not detail the revenue figures underpinning the guidance or how it compares with market expectations.
The players
Cochlear
Cochlear is an Australian hearing implant company that designs and manufactures cochlear implants and related hearing devices for people with hearing loss.
The details
Cochlear said trading between July and October remained in line with company expectations and that its August full-year assumptions still hold. The company also confirmed that North American president Lisa Aubert will depart later this year after 32 years with the business, ahead of a Capital Markets Day on Friday morning at its Macquarie University headquarters.
Timeline
July to October 2026: trading remained in line with company expectations.
August 2026: full-year results set the FY27 assumptions.
Friday, 13 November 2026: Capital Markets Day at Macquarie University headquarters.
Later in 2026: Lisa Aubert departs after 32 years with Cochlear.
Market Dynamics
The reaffirmation builds on the FY27 assumptions Cochlear set out in its August 2026 full-year results, signalling no change to its outlook in the months since. The company expects modest revenue growth in FY27, and the Capital Markets Day will set out its growth opportunities in the adult hearing implant market across developed markets.
Investors holding Cochlear shares can use the reaffirmed $330 million to $350 million FY27 profit guidance as a reference point ahead of the Capital Markets Day. The leadership change in North America is a factor to weigh alongside the company's outlook when reviewing any position.
The takeaway
Reaffirmed guidance from a company heading into an investor event signals management confidence without new numbers, so investors should look closely at the Capital Markets Day for details that were not included in this update.
What happens next
Cochlear will host its Capital Markets Day on Friday, 13 November 2026 at its Macquarie University headquarters, where it will outline growth opportunities in adult hearing implants and emerging evidence linking hearing loss treatment to cognitive health and fall prevention.
Further reading
For more on how listed companies communicate outlook changes, see Corporate Finance.
Source note: This article includes information reported by Capital Brief.






